Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018161798) IMPROVED ANTI-VEGFR-2 MONOCLONAL ANTIBODY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/161798 International Application No.: PCT/CN2018/076847
Publication Date: 13.09.2018 International Filing Date: 14.02.2018
IPC:
C07K 16/22 (2006.01) ,C12N 15/12 (2006.01) ,G01N 33/577 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/00 (2006.01) ,A61P 27/02 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
22
against growth factors
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
12
Genes encoding animal proteins
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
577
involving monoclonal antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27
Drugs for disorders of the senses
02
Ophthalmic agents
Applicants:
北京东方百泰生物科技有限公司 BEIJING DONGFANG BIOTECH CO., LTD. [CN/CN]; 中国北京市 大兴区北京经济技术开发区荣京东街2号1幢406室 Room 406, Building 1, No 2 Rongjing East Road Beijing Economic-Technological Development Area Daxing District, Beijing 100176, CN
Inventors:
白义 BAI, Yi; CN
谷香果 GU, Xiangguo; CN
Agent:
北京中济纬天专利代理有限公司 BEIJING WITAL PATENT AGENCY CO., LTD.; 中国北京市 朝阳区东三环北路甲2号8号楼0548室陆薇薇 LU, Weiwei Room 0549, 5th Floor, Jia No.2, East Sanhuan North Road, Chaoyang District Beijing 100027, CN
Priority Data:
201710130518.007.03.2017CN
Title (EN) IMPROVED ANTI-VEGFR-2 MONOCLONAL ANTIBODY
(FR) ANTICORPS MONOCLONAL ANTI-VEGFR-2 AMÉLIORÉ
(ZH) 一种改进的抗VEGFR-2单克隆抗体
Abstract:
(EN) The present invention belongs to the technical field of biomedicine. Provided are an improved anti-VEGFR-2 monoclonal antibody and an application thereof. By a computer-aided simulation design, a novel phage antibody library was designed, and an improved anti-VEGFR-2 monoclonal antibody was obtained after multiple rounds of screening. Both affinity and biological activity of said antibody are higher than the original antibody. Said antibody can effectively inhibit the binding of VEGFR-2 and a ligand thereof, VEGF, in vitro and can be used in treating a tumor and a disease caused by angiogenesis such as macular degeneration.
(FR) La présente invention se rapporte au domaine technique de la biomédecine. L'invention concerne un anticorps monoclonal anti-VEGFR-2 amélioré et son application. Par l'utilisation d'une conception de simulation assistée par ordinateur, une nouvelle banque d'anticorps de phage a été conçue, et un anticorps monoclonal anti-VEGFR-2 amélioré a été obtenu après de multiples cycles de criblage. Selon l'invention, l'affinité et l'activité biologique dudit anticorps sont supérieures à l'anticorps d'origine. L'anticorps de l'invention peut inhiber de manière efficace la liaison de VEGFR-2 et d'un ligand de celui-ci, VEGF, in vitro et peut être utilisé dans le traitement d'une tumeur et d'une maladie provoquée par une angiogenèse telle qu'une dégénérescence maculaire.
(ZH) 本发明属于生物医药技术领域,提供了一种改进的抗VEGFR-2单克隆抗体及其应用。本发明通过计算机辅助模拟设计,设计了新的噬菌体抗体库,经多轮筛选得到了改进的抗VEGFR-2单克隆抗体,所述抗体的亲和力和生物学活性均高于原抗,在体外能够很好地抑制VEGFR-2和其配体VEGF的结合,可用于治疗肿瘤和黄斑变性等新生血管引起的疾病。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)